Véronique Diéras

15PUBLICATIONS
77CO-AUTHORS
Clinical midwiferyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Jun 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.

Aditya Bardia, Hope S Rugo, Mina S Sedrak

|Jul 09, 2024
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Sara A Hurvitz, Aditya Bardia, Kevin Punie

|Jun 06, 2024
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

Hope S Rugo, Sara M Tolaney, Delphine Loirat

|Apr 25, 2024
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Sara A Hurvitz, Aditya Bardia, Kevin Punie

|Feb 29, 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.

Aditya Bardia, Hope S Rugo, Sara M Tolaney

Pageof 3

Frequent Collaborators

7 joint publications

Sara A Hurvitz

7 joint publications

Hope S Rugo

6 joint publications

Lisa A Carey

5 joint publications

Kevin Punie